| アブストラクト | INTRODUCTION: Rapid increased utilization of GLP-1s by US patients has raised safety concerns, in addition to challenges related to supply shortfalls starting in March 2022. METHODS: We analyzed publicly available FDA Adverse Event Reporting System (FAERS) data from January 2015 through December 2024 to describe adverse events where GLP-1s were the primary suspect and compared them with events involving injectable insulin products. RESULTS: Among the 112 532 reports analyzed, GLP-1s were associated with a higher share of administration-related reactions (63%) compared to insulin (39%). Reports of dosing issues and administration errors increased for GLP-1s beginning in Q4 2022 and rose further in 2023 and 2024, patterns not seen for insulin. Increases coincided temporally with the period of national GLP-1 shortages. Increases in reporting volume may reflect increased utilization rather than increased risk as FAERS lacks exposure denominators. CONCLUSION: The shift toward administration-related and dosing-related reports underscores the importance of patient and provider education and continued regulatory attention to the use of these drugs even as supply shortfalls resolve. Ongoing post-marketing surveillance remains essential to monitor safety signals. |
|---|
| ジャーナル名 | Health affairs scholar |
|---|
| Pubmed追加日 | 2026/2/25 |
|---|
| 投稿者 | Mattingly, T Joseph 2nd; Duru, Emeka Elvis; Conti, Rena M |
|---|
| 組織名 | Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake;City, UT 84112, United States.;Questrom School of Business, Boston University, Boston, MA 02215, United States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41737498/ |
|---|
